221 related articles for article (PubMed ID: 222448)
21. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
22. Postoperative immunostimulation after complete resection improves survival of patients with stage I nonsmall cell lung carcinoma.
Fujisawa T; Yamaguchi Y
Cancer; 1996 Nov; 78(9):1892-8. PubMed ID: 8909308
[TBL] [Abstract][Full Text] [Related]
23. [Transfer factor immunochemotherapy for primary lung cancer--evaluation of histologic types].
Fujisawa T; Yamaguchi Y
Gan No Rinsho; 1983 Oct; 29(12):1409-16. PubMed ID: 6315989
[TBL] [Abstract][Full Text] [Related]
24. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).
Giaccone G; Debruyne C; Felip E; Chapman PB; Grant SC; Millward M; Thiberville L; D'addario G; Coens C; Rome LS; Zatloukal P; Masso O; Legrand C
J Clin Oncol; 2005 Oct; 23(28):6854-64. PubMed ID: 16192577
[TBL] [Abstract][Full Text] [Related]
25. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
26. Randomized clinical trial of non-specific immunotherapy with cell-wall skeleton of Nocardia rubra.
Yasumoto K; Yamamura Y
Biomed Pharmacother; 1984; 38(1):48-54. PubMed ID: 6380607
[TBL] [Abstract][Full Text] [Related]
27. Survival of patients with bronchogenic carcinoma modified by BCG immunotherapy.
Warren SE; Crispen RG; Nika B
Am Surg; 1978 Jul; 44(7):428-31. PubMed ID: 686527
[TBL] [Abstract][Full Text] [Related]
28. Modified stage I (T1N0M0, T2N0M0), nonsmall cell lung cancer: treatment results, recurrence patterns, and adjuvant immunotherapy.
Little AG; DeMeester TR; Ferguson MK; Skinner DB; Hoffman PC; Skosey C; Blough RR; Golomb HM
Surgery; 1986 Oct; 100(4):621-8. PubMed ID: 3020725
[TBL] [Abstract][Full Text] [Related]
29. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
30. Effect of BCG cell-wall skeleton immunotherapy on the peripheral blood lymphocytes in patients with lung cancer after radiotherapy.
Nishikawa H; Yasaki S; Yoshimoto T; Sakatani M; Itoh M; Masuno T; Namba M; Ogura T; Hirao F; Azuma I; Yamamura Y
Gan; 1978 Dec; 69(6):819-24. PubMed ID: 750274
[TBL] [Abstract][Full Text] [Related]
31. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
32. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
33. Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative lung cancer patients.
Yasumoto K; Yaita H; Ohta M; Azuma I; Nomoto K; Inokuchi K; Yamamura Y
Cancer Res; 1985 Mar; 45(3):1413-7. PubMed ID: 3155992
[TBL] [Abstract][Full Text] [Related]
34. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
35. Gene-inducing program of human dendritic cells in response to BCG cell-wall skeleton (CWS), which reflects adjuvancy required for tumor immunotherapy.
Ishii K; Kurita-Taniguchi M; Aoki M; Kimura T; Kashiwazaki Y; Matsumoto M; Seya T
Immunol Lett; 2005 May; 98(2):280-90. PubMed ID: 15860229
[TBL] [Abstract][Full Text] [Related]
36. Aerosolized BCG (Tice strain) treatment of bronchogenic carcinoma: phase I study.
Cusumano CL; Jernigan JA; Waldman RH
J Natl Cancer Inst; 1975 Aug; 55(2):275-9. PubMed ID: 169370
[TBL] [Abstract][Full Text] [Related]
37. [Surgery and adjuvant therapy of non-small cell lung cancer].
Watanabe Y; Yamada T; Ichihashi T; Hashizume Y; Iwa T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1534-46. PubMed ID: 3524465
[TBL] [Abstract][Full Text] [Related]
38. [Role of immunotherapy in the combined treatment of lung cancer].
Trapeznikov NN; Gorodilova VV; Babakova SV; Kadagidze ZG; Trakhtenberg AKh
Vopr Onkol; 1982; 28(2):51-6. PubMed ID: 6278769
[No Abstract] [Full Text] [Related]
39. [Evaluation of postoperative immunotherapy of gastric cancer].
Ochiai T; Sato H
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):373-9. PubMed ID: 6349536
[TBL] [Abstract][Full Text] [Related]
40. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
